TLR3 and neoplasm: In this context, we and others have demonstrated that the delivery of a TLR3 agonist into the bronchoalveolar space reduces the presence of M2-associated arginase- and IL-10-positive AMs in tumor-bearing lungs [68, 69], possibly through an IFN-αβ dependent mechanism, as suggested [24, 70].